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Contr ncCHF cCHF ncCHF cCHF cCHF
vs Con vs Con vs ncCHF
n =21 n =29 n = 19 (P=) (P=) (P=)
sTNF.RI. nalml 0,6 + 0.061.1 + 0.18 1.7+ 0.170.03 0.02 <0.0001. . .. .... ....
sCD14, @/ml 2.7 + 0.11 3.2+ 0.16 3.8+23 0.07 0.0001 0.009
Leptin,n@ml 4.8 + 0.7 9.4+ 1.1 5.3+ 0.7 0.0005 NS 0,002
BodyFaffheight,@cm 106+10 123+9 60+ 5 0.20 0.03 0,0006
BodyLaatiheight, #cm 327 i 6 326 & 7 270 + 5 NS <0.0001 <0.0001
mean + SEM, nc = non-cechactlc,NS = p >0.20
overall, Ieptin correlated with fat tissue content (r = 0.70), ineulin (r =
0.72), weight and BMI (all p c 0.0001), but no! with cytokinee. Fat tiseue
content ve insulin (r= 0.49, p c 0.0001), vs sTNF-RI (r= –0.37), ve NA (r =
-0.34, troth p < 0.006). Lean tissue content sTNF-RI (r= –0.41), vs NA (r
= -0.39), veTNF-u (r = –0.36, all p < 0.003).
Corrclusiom Cardiac cachexia is not characteriead by Ieptin overproduc-
tion (anorexia via thie pathway is unlikely), but ie rather a Cataboliccondition
related to immune and neurohormonal activation.
m1083121 DiagnosticsndPrognosticValuaof SolublaInterleukin2 ReceptorintheSerumof Patients
withIdiopathicor lschemicDilated
Cardiomyopathy
G. Klappacher, D. Haab, M. Mehrabi, K. Plesch, R. Pacher, W. Kukutschki,
H.D. Glogar. University of Vienna, Vienna, Austria
We and others have recently reportad that circulating levels of soluble ln-
terleukin 2 receptor (sIL2R) are increased in patients with idiopathic dilated
cardiomyopathy suggesting cellular autoimmune activation. In the present
etudy we looked at the specificity, the diagnostic and predictive value of
serum sIL2R. In agreement with previous observations, 34 patients with
idiopathic dilated cardiomyopathy had higher Ievele of elL2R than healthy
controls (756 + 76.6 vs. 461.2 + 35.9 U/mL, p -=0.01). All 5 deaths during
the follow-up period of 690 * 57 days occurred among the patients with
serum elL2R >750 U/mL (log rank test, p e 0.00001), who also were more
likely to receive a heart transplant (odds ratio 6.5 (1.3-357.9)). Moreover,
patienta in NYHA claeeee Ill and IV, with eerum eodium <136 mmol/L and
furoeemide doeage z 100 mgfday had significantly higher serum concentra-
tion of sI12R than patiente in NYHA claesee I and 11,with eerum sodium ?
136 mmoVL and furosemide dosage <100 m~day, respectively. In 24 pe-
tiente with ieehemic cardiomyopathy eerum sIL2R was also increased above
control levels (619.7 + 36.3 U/mL, p c 0.025), but it was not associated
with the clinieel stage. Neither in ischemic nor in idiopathic dilated cardiomy-
opathy serum sIL2R correlated with the counts of CD2-, CD3-, CD4-, CD6-,
CD46R0-, and lL2R-positive cells in croee eecfione of the explantad hearte
of 15 transplant recipients among the total of 66 patients. Conclusion: Serum
sIL2R pradiete death and indicatee progression of dieeeee in patients with
idiopathic dilated cardiomyopathy. However, its increaae is not mnfinad to
the idiopathic form and does not necessarily reflect immune activation in the
myoeerdium.
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m1084135 LeftVentricularHypertrophylaAssociatedwithAbnormalAdenoalneAl-ReceptorSignalingand
Adenostne-inducedProteinKinaaeC Activation
S. Perlinl, E.P. Khoury, E.S. Chung, F. Bartl, R.A. Fenton, J.G. Dobeon,Jr.,
T.E. Meyer. Urriversityof Massachusetts Medical Cantec Worcester MA,
USA
To aesees the effect of prolonged adenosine (Ado) infueion on adrenergic
reeponsivensse (AR) in left ventricular hypartrophy (LVH), rat hearta were
isolated and perfused at 10 wke after aortic banding (B, heart weight index
increased by 50Yo) or sham surgery (S). AR (+dP/dk~) to 10-8 M isopro-
terenol was determined before (C) and at 60 min of 3.3 x 10-5M of Ado or
NaCl infueion, andafter 15, 30and45min of Ado waeh-out(tVO). Responses
were expressad as a % of C. This protocol was repeated with Ado and a)
a eeleetive AI antagonist, 6-cyclopentyl-1,3-diproPYlxanthine(lO-eM, CPX),
b) a protein kinase C (PKC) inhibitor, chelerythrine (2 x 10-6M, Chel) ore) a
PKC activator, phorbcd12-myristate 13-acetate (10-9M, PMA).
% dP/dt of C ‘A dP/dt of C followinaAdo WP
-w
60 mifl infusion: 15 rein: 30 mln: 45 mln:
S-NaCl (n = 7) 95+ 5 91 & 6 96% 6 96& 4
S-Ado (n= 10) 31 *6* 51 *4* 61 k 6“ 74• 9*
S-Ado +Chel (n = 13) 34* 3* S4• 5t 96 h 7t 99* 7t
S-NaCl (n =7) 97 i 4 96& 4 96& 4 99* 3
B-Ado (n =24) 50* 5*t 65+ 5*t 91 i 7t 99& 8t
B-Ado+ CPX (n =7) 56& 7“f 91 * 9t 97* 12t 101 * 14t
B-Ado + Chel (n =9) 38& 4*$ 99* fl 95* 3t 99 i 7f
B-Ado+ PMA (n = 4) 56& 7*f 60+ 7*# 67& 7** 72 & 10*#
Means k SEM; *p <0.05 vs NaCl; tp <0.05 vs S-Ado;#p <0.05 vs B-Ado.
Interstitial Ado levels returned to baseline within 5 min of WO. Ado expo-
sure in S caused a marked adrenergic depreeeion (AD) at 60 min of infusion.
AD persisted up to 45 min after Ado WO. This lingering AD was preventad
by PKC inhibition. In LVH the initial AD was Ieea marked and the rscovety
was much faeter. An Al-antagonist or a PKC inhibitor did not affeef this re-
sponse, whereas pronounced lingering AD wee elicited after PMA-induced
PKC activation. Conclusion: In LVH Al-receptor signaling and Ado-induced
PKC activation are abnormal.
I 1084-I36I AbnormalCalciumHandlingprOPerty
ProgressesfromtheAdjacentto Remote
Non-lrtfarctedMyocardiumafterMyocardial
Infarction
Y. Takemoto, M. Yoshiyama, K. Takeuchi, A. Hanateni, N. Shimizu,
H. Yamagishi, 1.Toda, J. Yoshikawa. First Department of Internal Medicine,
Osaka City IJniversifyMedical School, Osaka, Japan
Cardiac dysfunction after myocarclialinfarefion develops with time. However,
the cauae is still unknown. We have a hypothesis that abnormal calcium
handling pmpetty progresses fmm the adjacent non-infarcted left ventricle
(adjacent LV) to remote non-infarcted LV after myocerdial infarction (Ml) and
induces cardiac dysfunction. The purpose of this study was to examine the
time course of cardiac function by schoeerdiograms and gene expression in
the adjacent and remote LV and right ventricles (RV) of rate’at 1, 3 and 6
months after Ml in rate. (Each group n =6)
1 month 3 months 6 months
LVEDP ~mmHa} 22* 2** 25& 3** 26+3**
LVEDV ~m!Jkg)-’ 1.52 +0.14’”
LVEF (“A) 35+3**
LVwt (@kg) 2.16+ 0.19’
RVwt (@kg) 0.74* 0.10”
E velocity(cnVs) 84& 2
A velocity(cWS) 22+ 3
EIA 4.2 + 0.5”
E Decele (rdsz) 16.1 &2.t*
1,70+ 0.13**
30*4**
2.29 + 0.17””
0.86 *0.11””
95 *3*
16 *3*
9.5* 2.2**
22.3 h 2.6**
1.96+ 0.16**
26*4”*
2.42 & 0.20**
0,92 + 0.14””
101 *3*
12 +3*
12.3+2.1””
30.4* 1.7**
SR Ca (foid)
AdjacentLV 1.0+ 0.2 0.7 l 0.1” 0.3+0.0””
Remote LV 1.0 l 0.1 1.* 0.1 0.7 l 0.0*
Rv 1.0 i 0.2 0,7+ 0.2” 0.6 + O.l”+,.
Na-Ca (told)
AdjacentLV 1.6 + 0.2** 0.9 * 0.1 0.5+ 0.1””
Remote LV 1.9 * 0.2”’ 1.8 +0.2”” 1.0 +0.1
RV 2.0 + 0.2”” 1.6 & 0.2”” 1.1 +0.2
*P <0,05, **P < 0,01: comparedto sham operated rats
Gene expressions of fetal contractile proteins (~-myosin heavy chain,
a-ekeletal aetin, ANP) and collagen 1,Ill were highest at 1 M after Ml. In
conclusion, cardiac dysfunction, decreased gene expression of SR-Ca and
Na-Ca advanced from the adjacent to remote LV with time.
11084-137I EffecteofNitricOXideSYntha*lnhibitiononthe
VenousTonein RatawithHeatiFailure
T. Hirai, H. Asanoi, T.1.Musch, H. Inoue. ToyarrsaMedical& Pharmaceutical
University Toyama,Japan, Kanaas State Universi~ Manhattan, KS, USA
Recent studies have demonstrated that nitric oxide (NO) mcdulatee bseeline
venous tone. To determine the functional mle of NO in the regulation of va-
noustone in normal rats and rats with chronic heart failure (CHF), we etudied
the effect of NG-nitro-L-arginine methyl ester (L-NAME), an inhibitor of NO
synthesis, in chloralose-anesthetized Wister rats with CHF due to myoeerdlal
infarction (Ml; n = 11) (Ml eize; 41 + 5% of the left ventricular endocerdial
circumference) and sham operatad rats (SHAM; n = 10). Mean circulatory
filling preesure (MCFP), the equilibrated eystemic pressure occurring when
the circulation is arrestad by transient inflation of a balloon in the right atrium,
was meaeured before and after L-NAME (1, 3, 10, 20 mg/kg, iv.) adminis-
tration. MCFP was used as an index of total venoua capacitance. Baseline
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measurements demonstrated that rats with CHF had decreased LVSP,ele-
vated LVEDP and reduced LVdP/dt compared to SHAM (p < 0.05). Before
L-NAME administration, MCFP in CHF was significantly greater compared to
SHAM (p < 0.01). L-NAME dose-dependently incressed mean arterial pres-
sure and decreased heart rate in both SHAM and CHF rats. After L-NAME
administration, MCFP waa increased in both groups (p < 0.01) (from 8.7 *
0.5 to 9.3+ 0.7 mmHg in CHF; from 6.8 + 0.4 to 7.9 + 0.6 mmHg in SHAM).
Changes in MCFP following L-NAME was significantly decreased in CHF
(+6.9 +=1.0% from control levels) when compared to SHAM (+15.6+ 1.3%).
These results indicate that NO mediated regulation of venous tone could be
impaired in a rat model of CHF.
p] Plasma AdenosineLevels in.rea*inPatlents
with Congestive Heert Fellure
H. Funaya, M. Kltakeze, T. Minamino, K. Node, M. Hori. The First fJept. of
Med., Oaska Univ., Osaka, Japan
Adenosine is known to be cardioprotective via adenosine Al and A2 recep-
tors against cardiovascular impairment. We examined whether the plasma
adenosine levels are increased or decreased in patients with heart failure.
seventy-six patients (mean 52 + 2 years old, ranging 25-61) attending the
apecialiats of heart failure clinic over 6 months were divided according to
the cause of haarf failure (40 patients with ischemic heart diseaaes, and
36 patients with congestive heart failure due to vascular heart diseases (12
patients with mitral regurgitation, and 5 patients with aortic regurgitation),
hyparfrophic obatruetive cardiomyopathy (5 patients), and dilated cardiomy-
opathy (14 patients). Controls were 24 healthy laboratory staff members
(mean 36 + 2 yearsold, ranging 25-56). The plasma adenosine levels in-
creased according to the NYHA classification (1= 99 + 11, II = 166 i 15, Ill
= 343& 35, IV= 298 +57 vs. 73+ 10 (healthy subjects) nmol/L). Although
ejection fraction (NYHA I = 71 & 2, NYHA Ii = 64 * 4, NYHA Ill = 37 + 3,
NYHA IV = 23 + 6%) decreased In patients with hean failure, there was no
direct correlation (r= 0.161, NS) between EF and the plasma adenosine lev-
els in the patients with heart failure. There were no significant differences in
the plasma adenosine levels in the patients with ischemic and non-ischemic
heart failure (219 + 30 and 211 * 23 nmol/L). The plasma norepinephrine
levels were also increased according to NYHAclaasification (NYHA I = 116+
15, NYHA II = 337 + 26, NYHA Ill= 684+ 45, NYHA IV = 1232 + 117VS.84
* 7 (healthy subjects) pg/ml). There was a correlation (r= 0.414, P < 0.05)
between the plasma adenosine and norepinephrine levels in the patients
with heart failure. Plaama adenosine levels were independent of drugs usad
in heart failure (i.e., diuretics (p = 0.91), digitalis (p = 0.08), beta-blockers
(P= 0.42), Ca blockers (P = 0.18), isosorbide dinitrates (p = 0.26) and ACE
inhibitora (p= 0.19)). We conclude that the plasma adenosine Ievals increase
in patients with ischemic and non-ischemic hearf failure, and that the extents
of increases in adenosine levels correlate well with the severity of heart fail-
ure. Increased plasma adenosine levels may be endogenous compensatory
mechanisms for the failing heart.
H1084139 Increased Plesma Nitrate Concentration in HeartFailure is Due to Decreaaed Renal Nitrate
Clearance
S.D. Katz, T. Khan. Columbia University College of Physicians and
Surgeons, New York Cify NY USA
Despiteevidence of attenuated endothelium-dependent, nitricoxide-mediated
veeodiiation in patients with congestive heari failure (CHF), plasma con-
centration of nitrate (NOS), the stable metabolize of nitric oxide, has been
reported to be increased in patients with CHF when compared with that of
normal subjects. Whether increased plasma NOS concentration in CHF is
due to increased endothelial nitric oxide production or reduced renal clear-
ance of nitrates is unknown. Accordingly, renal NOSclearance (ml/min) was
determined in 6 patients with Class Ill CHF (mean age 51, mean EF 26%)
and 5 normal subjects (mean age 45 years) by measuring 24-hour urine
volume (ml), and urine and plasma N03 concentrations (MM) with a nitric
oxide chemikrminescence analyzer (Sievere Model 270B). Results were as
follows:
24hr.Urtne PlasmsN03 UrineN03 RenslNO~
Volume (uM) IuM) Clesrsnce
Normals 1910 10.6 419 59
CHF 1904 31.5” 172” 13”
*indicatesp <0.05 vs.normale
Creatinine clearance was also decreased in CHF when compared with
normals (83 vs. 133 mVmin, p < 0.05). Plasma nitrate concentration cor-
related with both nitrate clearance and creatinine clearance (r = 0.60 and
0.65, both p < 0.05). In conclusion, theae data confirm the previous repott
of increased plasma N03 wncentration in CHF and furthar demonstrate
that 24-hour urinary N03 excretion and renal N03 clearance are markadly
decreased in CHF. Thesa data suggest that increased plasma N03 in CHF
is due to decreased renal N03 clearance rather than increased endothelial
nitric oxide production,
~1084-14OI Effects of NasalO.~genon Muscle Sympathetic
Activity in Patients with Congestive Heert Failure
G. Nell, S. Andreas, R.R. Wenzel, T.F.LUscher.Cardio/og~ Univer’dfy
Hospital Bern, Swirzerfand
In patients with congestive heart failure activation (CHF) of sympathetic
nervous system occurs and importantly influences prognosis. We recently
obsewed an improvement of exercise capacity following the treatment of
Cheyne-Stokes respiration (CSR) with nasal oxygen in patients with CHF
and attributed this to the reduction of CSR and oxygen desaturations with
concomitant reduction in sympathetic activity. We therefore Investigated the
effects of nasal oxygen (4 L/rein over 20 rein) on muacle sympathetic nerve
activity (MSA) at rest and during a voluntary apnea in patients with chronic
CHF. In 6 patients (age 5 + 9 years; ejection fraction 22 & 4%) MSA was
measured using micronaurography of the peronaal nerve. Resting MSA was
higher in CHF patients compared healthy controls (n = 21, age: 27 + 16
yeara; 72 + 15 vs 41 +21 bursta/100 heartbeats; p < 0.01). InCHF patients
resting MSAwas not influenced by oxygen administration (72+ 16bu~tsdltltl
heartbeats; n.s.), but arterial oxygen saturation increased from 93 + 370to
98 * 1% (p < 0.01) and heart rate decreased from 91 + 15 to 88 A 17
beats/rein (p -=0.05), but blood pressure was unaffected. The duration of
apnea was longer in healthy volunteers compared to CHF patiente (4o + 9 vs
23 i 6 sac, p < 0.001), but it increased during oxygen administration to 32 +
7 sec in CHF patients (p< 0.05). Exposed to room air, the increase In MSA
during apnea was comparable in CHF patienta and healthy volunteers (13
+ 9 vs 15 * 8 bursts/100 heartbeats; n.s.), In CHF patients, the increaae in
MSA durfng apnea was attenuatecby oxygen (13+9 va 2 + 17 bursta/100
heartbeats; p < 0.05), whereas changes in blood pressure and heart rate
were unaffected,
Thus, oxygen administration attenuates the increaae in MSAduring apnea
in patienta with CHF. Aa repetitive apnea episodes during Cheyne-Stokes
respiration in CHF patients could be of pathophyeiologic relevance, in par-
ticular for prognosis, Iongterm effacfe of oxygen administration should be
further tested,
I lo84-141j f3:3:;:Ceptorsand Beta-Blocltersin Heart
J.E. Sanderson, L.Y.Yeung, S.K. Chan, C.M. Yu, R. Kay, L. Bemardi 1. The
Chinese University of Hong Kong, Shatin, Hong Kong, 1University of Pavia,
Italy
Autonomic imbalance and depression of baroreeeptor function relate to prog-
nosis and rick of sudden death in heari failure (HF). It ia not known to what
extent treatment with b-blockers (BB) improve these aspects and if there are
differences between BBs. We assessed baroreeeptor gain noninvasively by
spectral anaiyeie of RR and systolic blood pressure intervals (258-512) and
respiratory signal recorded at rest, supine and standing with sponteneoua
and controlled respiration using the cross-spectral method when coherence
was >0.5 (a-angle). Patienta received either hydrophilic celiprolol (C) 200
mg daily (n = 21), Iipophilic metoprolol (M) 50 mg B.D. (n = 19) or placebo (n
= 10) for 12 weeks after a 4 week dose titration period.
Resu/te: Baroraoaptor gain was significantly depressed in patients com-
pared to a control group (4.95 A 0.55; normal 11.73 ~ 1.32 mseo/mmHg;
p < 0.0001), After treatment with M baroreceptor gain improved from 4.5
+ 1.05 to 9.06 l 1.6 mseo/mmHg (p = 0.008) and the effect was apparent
after 4 weeks treatment. In ccmtrastthe changes in Lmroreceptorgain after
treatment with C (4.97& 1.12 to 6.13 + 1.17 msac/mmHg) or placebo (6.52
A 1.55 to 5.47 & 1.54 msac/mmHg) were not significant. Thus M has a
superior effect on restoring baroreoeptor gain towards normal which may be
due to a direct central effect of M which is absent with hydrophilic BBs such
as C.
11084-142] DiaStOlicD~SfUnctiOnPmdicta Abnormal
Baroreflex Benaitivity in Heart Failure
E.Eleuteri, P.Lanfranchi, P.L.Temporelli, G. Mazzu’are,P.Giannuzzi.
Cardiology Division, S. Maugeri Foundation, IRCCS, Veruno, Italy
Abnormal baroreflex sensitivity (BRS) has been documented inchronichaart
failure (CHF) patients (pts), howeverits clinical relevancehas stili to be
clarified.The relationshipbetweenleft ventricular(LV)dysfunction,clinical
impairmentand BRSwas investigatedin 138 consecutiveCHF pte with
